$XBI $124.01 -0.31%
Covid Updates
$PFE +0.9% & BNTX -0.9% FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years source
$MRNA -1.1% Moderna Announces Swissmedic Authorizes Booster Dose of Moderna’s COVID-19 Vaccine source
Pipeline Updates
$PSNL -1.1% Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development source
$ANGN -56.6% ANGION AND VIFOR PHARMA REPORT TOPLINE RESULTS FROM PHASE 3 TRIAL OF ANG-3777 IN KIDNEY TRANSPLANT PATIENTS AT RISK FOR DELAYED GRAFT FUNCTION source
$NRIX +2.6% Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit source
$CRTX -2.7% Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression source
$MRNA -1.1% Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine source
$PGEN +.2% Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors source
$INO -1.4% INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa source
$VXRT -0.4% Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial source
$LCTX +0.4% OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D source
$PRVB -1.0% Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 source
$ALKS -0.9% Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer source
$KRYS +0.9% Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa source
$MCRB -1.6% SERES THERAPEUTICS PRESENTS LATE-BREAKING PHASE 3 DATA ON INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-109 IN RECURRENT C. DIFFICILE INFECTION AT AMERICAN COLLEGE OF GASTROENTEROLOGY 2021 ANNUAL SCIENTIFIC MEETING source
$GILD 0.0% Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults source
$SQZ +11.2% SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint Inhibitors source
$HGEN +5.6% First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML) source
Financial & Business Updates
$PHAT +2.0% Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock source
$EVAX -13.0% Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital source
Posted by JM
Comments